查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
GLP-1市場：產業趨勢與全球預測（~2035）-依分子類型、使用的活性化合物、GLP-1促效劑類型、GLP-1促效劑、給藥途徑、目標適應症、地區主要藥物開發公司的銷售預測
市場調查報告書
商品編碼
1534571

GLP-1市場：產業趨勢與全球預測（~2035）-依分子類型、使用的活性化合物、GLP-1促效劑類型、GLP-1促效劑、給藥途徑、目標適應症、地區主要藥物開發公司的銷售預測

GLP-1 Market: Industry Trends and Global Forecasts, till 2035 Distribution by Type of Molecule, Active Compound Used, Route of Administration, Target indication, Geography, Leading Drug Developers and Sales Forecast
出版日期: | 出版商: Roots Analysis | 英文 218 Pages | 商品交期: 最快1-2個工作天內

價格

估計2024年 GLP-1 市場規模將達到 493億美元，2024-2035年預測期間年複合成長率為 11.1%。

GLP-1 受體促效劑是一類主要用於控制第2 型糖尿病患者血糖/血糖值的藥物。此外，一些GLP-1促效劑還可以幫助治療肥胖和相關的心臟疾病（心血管疾病）。根據Lancet期刊的一項研究，42.4%的美國成年人患有肥胖症。此外，根據世界衛生組織（WHO）的資料，肥胖每年導致 400 萬人死亡。此外，全球約有5.3億成年人患有糖尿病，其中98%患有第2型糖尿病，預計到2050年，糖尿病盛行率將增加到約13億。值得注意的是，根據美國糖尿病協會的資料，糖尿病是2021年第八大死因。

近年來，社群媒體、名人代言和直接針對消費者的廣告的影響力日益增強，導致消費者生活方式發生重大變化。預計這將導致減重和 2 型糖尿病治療解決方案的需求激增，刺激該領域的創新和市場擴張。為了滿足對第2 型糖尿病治療和體重管理藥物日益成長的需求，公司採取各種措施來開發針對這些適應症的治療方法。其中，由於持續的研究和開發努力以及許多臨床試驗的良好結果，GLP-1促效劑已成為一種有前途的選擇。

過去幾年，許多針對肥胖和第2型糖尿病的GLP-1藥物已在全球獲得批准。2024年，Novo Nordisk開發的Wegovy被FDA批准用於治療肥胖或超重成年人的嚴重心臟病。 GLP-1 市場，也稱為GLP-1 受體促效劑市場，鑑於這些藥物的利潤潛力，吸引了私人和公共投資者的極大關注，預計在預測期內將成長，這導致了巨大的市場。

本報告調查了全球GLP-1 市場，提供市場概況，及按分子類型、使用的活性化合物、GLP-1 促效劑類型、GLP-1 促效劑、給藥途徑、目標適應症、地區的趨勢，以及進入市場的公司簡介。

目錄

第1章 背景

第2章 研究方法

第3章 經濟與其他專案特定考量

第4章 執行摘要

第5章 簡介

第6章 市場現況：GLP-1藥物

第7章 GLP-1 藥物：詳細公司簡介

第8章 GLP-1 藥物：公司簡介

第9章 夥伴關係與協作

第10章 市場影響分析：驅動因素、限制因素、機會、挑戰

第11章 全球 GLP-1 市場

  • 假設與研究方法
  • 全球 GLP-1 市場、歷史趨勢與2035年預測

第12章 GLP-1 市場，依分子型態

第13章 GLP-1 市場，依所使用的活性化合物

第14章 GLP-1 市場，依 GLP-1 促效劑類型

第15章 GLP-1 市場，依 GLP-1 促效劑

第16章 GLP-1 市場，依給藥途徑

第17章 GLP-1 市場，依目標適應症

第18章 GLP-1 市場，依地區

第19章 GLP-1市場，GLP-1藥物銷售預測

第20章 GLP-1 市場，依主要藥物開發公司

第21章 附錄 1：表格資料

第22章 附錄 2：公司與組織名單

Product Code: RA100502

The GLP-1 Market is valued at USD 49.3 billion in 2024 growing at a CAGR of 11.1% during the forecast period 2024-2035.

GLP-1 receptor agonists are a class of medications primarily utilized for managing blood sugar levels / glucose levels in individuals with type 2 diabetes. Further, a few GLP-1 agonists can also help in the treatment of obesity and related heart disease (cardiovascular disease). It is important to mention that, according to a study conducted by Lancet, 42.4% of adult individuals in the US are obese. Moreover, according to the World Health Organization (WHO), 4 million people die annually due to obesity. In addition, nearly 530 million global adult population suffer from diabetes, with 98% of those having type 2 diabetes and prevalence of diabetes is expected to increase to nearly 1.3 billion by 2050, making it a significant public health concern. It is worth mentioning that, according to the American Diabetes Association, diabetes was the eighth leading cause of death in 2021.

In recent years, there has been a notable shift in consumer lifestyles driven by the growing influence of social media, celebrity endorsements and direct-to-consumer advertising. This has led to a surge in the demand for weight loss and type 2 diabetes treatment solutions, which is likely to spur innovation and market expansion in this domain. In order to address the increasing demand for type 2 diabetes and body weight management drugs, various initiatives have been undertaken by players to develop drugs for treatment of such indications; of these, GLP-1 agonist drugs have emerged as promising option driven by the significant number of positive clinical trial results, along with continuous research and development efforts.

Over the past few years, a number of GLP-1 drugs targeting obesity and type 2 diabetes have received regulatory approvals globally. In 2024, the FDA approved Wegovy, developed by Novo Nordisk, for the treatment of serious heart problems in adults with obesity or overweight. Given the lucrative potential of these drugs, the GLP-1 market, also known as GLP-1 receptor agonist market, has gained significant attention of both private and public investors leading to the substantial market growth during the forecast period.

Key Market Segments

Type of Molecule

  • Biologics
  • Small Molecules

Active Compound Used

  • Dulaglutide
  • Liraglutide
  • Orforglipron
  • Retatrutide
  • Semaglutide
  • Survodutide
  • Tirzepatide
  • Other Active Compounds

Type of GLP-1 Agonist Drugs

  • Long-acting GLP-1 Agonist
  • Short-acting GLP-1 Agonist

Type of Agonist

  • Single agonist
  • Dual agonist
  • Tri-agonist

Route of Administration

  • Oral
  • Parenteral

Target Indication

  • Alzheimer's Disease
  • Non-Alcoholic Steatohepatitis
  • Obesity
  • Sleep Apnea
  • Type 2 Diabetes

Key Geographical Regions

  • North America
  • Europe
  • Asia Pacific
  • Latin America

Leading Drug Developers

  • Boehringer Ingelheim
  • Eli Lilly
  • Novo Nordisk
  • Other Developers

Research Coverage:

  • A detailed assessment of the overall market landscape of GLP-1 drugs, along with information on several relevant parameters, such as stage of development (Marketed, Clinical (Phase III, Phase II, Phase I), IND-Enabling and Discovery / Preclinical), type of molecule (biologics and small molecules), active compound used (ecnoglutide, efocipegtrutide, exenatide, froniglutide, isupaglutide, liraglutide, lixisenatide, semaglutide, tirzepatide, utreglutide and other active compounds), GLP-1 agonist (single-agonist, dual-agonist and tri-agonist), route of administration (intraarticular, oral, subcutaneous and sublingual), dosing frequency (single dose, once monthly, once weekly, twice weekly, once daily and twice daily), type of therapy (combination therapy and monotherapy), target indication (Alzheimer's disease, congenital hyperinsulinism, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis (NASH drugs), obesity, obstructive apnea syndrome, Parkinson's disease, sarcopenia, type 2 diabetes and other target indication) and therapeutic area (genetic disorders, inflammatory disorders, metabolic disorders, neurological disorders, neuromuscular disorders, respiratory disorder and other therapeutic areas). In addition, the chapter provides a detailed list of developers engaged in developing GLP-1 drugs, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters (North America, Europe and Asia-Pacific and Rest of the world) of the players involved in this market space.
  • Elaborate profiles of prominent players developing GLP-1 drugs (shortlisted based on the number of drugs in its pipeline). Each profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and leadership team), financial information, drug portfolio, recent developments and an informed future outlook.
  • A detailed analysis of the partnerships inked between stakeholders in the GLP-1 industry, based on several parameters, such as year of partnership, type of partnership, type of molecule, type of partner and most active players (in terms of the number of partnerships signed) and regional distribution of partnership activity in this domain, since 2020
  • An in-depth analysis of the factors that can impact the growth of GLP-1 companies. It also features identification and analysis of key GLP-1 market drivers, potential restraints, emerging opportunities, and existing challenges.
  • A detailed GLP-1 receptor agonist market forecast analysis in order to estimate the existing market size and future opportunity for GLP-1 companies over the next decade. Based on multiple parameters, such as likely adoption trends, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within the global GLP-1 receptor agonist market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
  • Detailed projection of the current and future opportunity within the GLP-1 market across different types of molecules, namely biologics and small molecules.
  • Detailed projection of the current and future opportunity within the GLP-1 receptor agonist market across different active compound used, namely dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide and other active compounds.
  • Detailed projection of the current and future opportunity within the GLP-1 industry across different types of GLP-1 agonist drug, namely long-acting GLP-1 agonist and short-acting GLP-1 agonist.
  • Detailed projection of the current and future opportunity within the GLP-1 industry across different types of agonists, namely single-agonist, dual-agonist and tri-agonist.
  • Detailed projection of the current and future opportunity within the GLP-1 receptor agonist market across different routes of administration, namely oral and parenteral.
  • Detailed projection of the current and future opportunity within the GLP-1 market across different target indication, namely Alzheimer's disease, non-alcoholic steatohepatitis, obesity, sleep apnea, type 2 diabetes.
  • Detailed projection of the current and future opportunity within the GLP-1 industry across different key geographical regions, namely North America, Europe, Asia-Pacific and Latin America.
  • Detailed projections of the current and future GLP-1 market for the sales of forecasted drugs.
  • Detailed projections of the current and future revenues from the sales of drugs developed by the leading players, namely Boehringer Ingelheim, Eli Lilly, Novo Nordisk and other players.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the GLP-1 Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • AstraZeneca
  • Biolingus
  • Boehringer Ingelheim
  • D&D Pharmatech
  • Eli Lilly
  • Gmax Biopharm
  • Hanmi Pharmaceutical
  • Innogen
  • Novo Nordisk
  • PegBio
  • Pfizer
  • QL Biopharma
  • Roche
  • Sanofi
  • Sciwind Biosciences
  • Tonghua Dongbao Pharmaceutical
  • Viking Therapeutics
  • Vivani
  • vTv Therapeutic

TABLE OF CONTENTS

1 BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2 RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors affecting Currency Fluctuations and Foreign Exchange Rates
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on Market
      • 3.2.2.4. Strategies For Mitigating Foreign Exchange Risk
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4 EXECUTIVE SUMMARY

5 INTRODUCTION

  • 5.1. Overview of the GLP-1 Drug
    • 5.1.1. Challenges Associated with GLP-1 Drugs
    • 5.1.2. Mechanism of Action of GLP-1 Drugs
  • 5.2. Important Facts in GLP-1 Domain
  • 5.3. Future Perspectives

6 MARKET LANDSCAPE: GLP-1 DRUGS

  • 6.1. GLP-1 Drugs: Market Landscape
    • 6.1.1. Analysis by Status of Development
    • 6.1.2. Analysis by Type of Molecule
    • 6.1.3. Analysis by Active Compound Used
    • 6.1.4. Analysis by Type of Agonist
    • 6.1.5. Analysis by Route of Administration
    • 6.1.6. Analysis by Dosing Frequency
    • 6.1.7. Analysis by Type of Therapy
    • 6.1.8. Analysis by Target Indication
    • 6.1.9. Analysis by Therapeutic Area
  • 6.2. GLP-1 Drugs: Developer Landscape
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Location of Headquarters
    • 6.2.4. Analysis by Location of Headquarters (Country) and Status of Development
    • 6.2.5. Most Active Developers: Analysis by Number of Therapies

7 GLP-1 DRUGS: DETAILED COMPANY PROFILES

  • 7.1. Chapter Overview
    • 7.1.1. AstraZeneca
      • 7.1.1.1. Company Overview
      • 7.1.1.2. Pipeline Portfolio
      • 7.1.1.3. Financial Details
      • 7.1.1.4. Recent Developments and Future Outlook
    • 7.1.2. D&D Pharmatech
      • 7.1.2.1. Company Overview
      • 7.1.2.2. Pipeline Portfolio
      • 7.1.2.3. Financial Details
      • 7.1.2.4. Recent Developments and Future Outlook
    • 7.1.3. Eli Lilly
      • 7.1.3.1. Company Overview
      • 7.1.3.2. Pipeline Portfolio
      • 7.1.3.3. Financial Details
      • 7.1.3.4. Recent Developments and Future Outlook
    • 7.1.4. Novo Nordisk
      • 7.1.4.1. Company Overview
      • 7.1.4.2. Pipeline Portfolio
      • 7.1.4.3. Financial Details
      • 7.1.4.4. Recent Developments and Future Outlook
    • 7.1.5. Pfizer
      • 7.1.5.1. Company Overview
      • 7.1.5.2. Pipeline Portfolio
      • 7.1.5.3. Financial Details
      • 7.1.5.4. Recent Developments and Future Outlook
    • 7.1.6. Sanofi
      • 7.1.6.1. Company Overview
      • 7.1.6.2. Pipeline Portfolio
      • 7.1.6.3. Financial Details
      • 7.1.6.4. Recent Developments and Future Outlook
    • 7.1.7. Tonghua Dongbao Pharmaceutical
      • 7.1.7.1. Company Overview
      • 7.1.7.2. Pipeline Portfolio
      • 7.1.7.3. Financial Details
      • 7.1.7.4. Recent Developments and Future Outlook
    • 7.1.8. Vivani
      • 7.1.8.1. Company Overview
      • 7.1.8.2. Pipeline Portfolio
      • 7.1.8.3. Financial Details
      • 7.2.8.4. Recent Developments and Future Outlook

8 GLP-1 DRUGS: BRIEF COMPANY PROFILES

  • 8.1. Chapter Overview
    • 8.1.1. Biolingus
      • 8.1.1.1. Company Overview
      • 8.1.1.2. Pipeline Portfolio
    • 8.1.2. Boehringer Ingelheim
      • 8.1.2.1. Company Overview
      • 8.1.2.2. Pipeline Portfolio
    • 8.1.3. Gmax Biopharm
      • 8.1.3.1. Company Overview
      • 8.1.3.2. Pipeline Portfolio
    • 8.1.4. Hanmi Pharmaceutical
      • 8.1.4.1. Company Overview
      • 8.1.4.2. Pipeline Portfolio
    • 8.1.5. Innogen
      • 8.1.5.1. Company Overview
      • 8.1.5.2. Pipeline Portfolio
    • 8.1.6. PegBio
      • 8.1.6.1. Company Overview
      • 8.1.6.2. Pipeline Portfolio
    • 8.1.7. QL Biopharma
      • 8.1.7.1. Company Overview
      • 8.1.7.2. Pipeline Portfolio
    • 8.1.8. Roche
      • 8.1.8.1. Company Overview
      • 8.1.8.2. Pipeline Portfolio
    • 8.1.9. Sciwind Biosciences
      • 8.1.9.1. Company Overview
      • 8.1.9.2. Pipeline Portfolio
    • 8.1.10. Viking Therapeutics
      • 8.1.10.1. Company Overview
      • 8.1.10.2. Pipeline Portfolio
    • 8.1.11. vTv Therapeutics
      • 8.1.11.1. Company Overview
      • 8.1.11.2. Pipeline Portfolio

9 PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. GLP-1 Market: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Focus Area
    • 9.3.4. Analysis by Year and Type of Partnership
    • 9.3.5. Most Active Players: Analysis by Number of Partnerships
    • 9.3.6. Analysis by Geography
      • 9.3.6.1. Intercontinental and Intracontinental Deals
      • 9.3.6.2. Local and International Deals

10 MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 10.1. Chapter Overview
  • 10.2. Market Drivers
  • 10.3. Market Restraints
  • 10.4. Market Opportunities
  • 10.5. Market Challenges
  • 10.6. Conclusion

11 GLOBAL GLP-1 MARKET

  • 11.1. Assumptions and Methodology
  • 11.2. Global GLP-1 Market, Historical Trends and Forecasted Estimates, till 2035
    • 11.2.1. Scenario Analysis
      • 11.2.1.1. Conservative Scenario
      • 11.2.1.2. Optimistic Scenario
    • 11.2.2. Key Market Segmentations

12 GLP-1 MARKET, BY TYPE OF MOLECULE

  • 12.1. Assumptions and Methodology
  • 12.2. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
    • 12.2.1. GLP-1 Market for Biologics, till 2035
    • 12.2.2. GLP-1 Market for Small Molecules, till 2035
  • 12.3. Data Triangulation and Validation

13 GLP-1 MARKET, BY ACTIVE COMPOUND USED

  • 13.1. Assumptions and Methodology
  • 13.2. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
    • 13.2.1. GLP-1 Market for Dulaglutide, till 2035
    • 13.2.2. GLP-1 Market for Liraglutide, till 2035
    • 13.2.3. GLP-1 Market for Orforglipron, till 2035
    • 13.2.4. GLP-1 Market for Retatrutide, till 2035
    • 13.2.5. GLP-1 Market for Semaglutide, till 2035
    • 13.2.6. GLP-1 Market for Survodutide, till 2035
    • 13.2.7. GLP-1 Market for Tirzepatide, till 2035
    • 13.2.8. GLP-1 Market for Other Active Compounds, till 2035
  • 13.3 Data Triangulation and Validation

14 GLP-1 MARKET, BY TYPE OF GLP-1 AGONIST DURGS

  • 14.1. Assumptions and Methodology
  • 14.2. GLP-1 Market: Distribution by Type of GLP-1 Agonist Drugs, 2020, 2024 and 2035
    • 14.2.1. GLP-1 Market for Long-acting GLP-1 Agonist, till 2035
    • 14.2.2. GLP-1 Market for Short-acting GLP-1 Agonist, till 2035
  • 14.3. Data Triangulation and Validation

15 GLP-1 MARKET, BY GLP-1 AGONIST

  • 15.1. Assumptions and Methodology
  • 15.2. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
    • 15.2.1. GLP-1 Market for Single-agonist, till 2035
    • 15.2.2. GLP-1 Market for Dual-agonist, till 2035
    • 15.2.3. GLP-1 Market for Tri-agonist, till 2035
  • 15.3. Data Triangulation and Validation

16 GLP-1 MARKET, BY ROUTE OF ADMINISTRATION

  • 16.1. Assumptions and Methodology
  • 16.2. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
    • 16.2.1. GLP-1 Market for Oral Route, till 2035
    • 16.2.2. GLP-1 Market for Parenteral Route, till 2035
  • 16.3. Data Triangulation and Validation

17 GLP-1 MARKET, BY TARGET INDICATION

  • 17.1. Assumptions and Methodology
  • 17.2. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
    • 17.2.1. GLP-1 Market for Alzheimer's Disease, till 2035
    • 17.2.2. GLP-1 Market for Non-Alcoholic Steatohepatitis, till 2035
    • 17.2.3. GLP-1 Market for Obesity, till 2035
    • 17.2.4. GLP-1 Market for Sleep Apnea, till 2035
    • 17.2.5. GLP-1 Market for Type 2 Diabetes, till 2035
  • 17.3. Data Triangulation and Validation

18 GLP-1 MARKET, BY GEOGRAPHY

  • 18.1. Assumptions and Methodology
  • 18.2. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
    • 18.2.1. GLP-1 Market in North America, till 2035
    • 18.2.2. GLP-1 Market in Europe, till 2035
    • 18.2.3. GLP-1 Market in Asia-Pacific, till 2035
    • 18.2.4. GLP-1 Market in Latin America, till 2035
  • 18.3. Data Triangulation and Validation

19 GLP-1 MARKET, SALES FORECAST OF GLP-1 DRUGS

  • 19.1. Chapter Overview
  • 19.2. Approved GLP-1 Drugs: Sales Forecast
    • 19.2.1. Feisumei (Benaglutide) Sales Forecast
    • 19.2.2. Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast
    • 19.2.3. Mounjaro (Tirzepatide) Sales Forecast
    • 19.2.4. Ozempic (Semaglutide Subcutaneous) Sales Forecast
    • 19.2.5. Rybelsus (Semaglutide Oral) Sales Forecast
    • 19.2.6. Saxenda (Liraglutide) Sales Forecast
    • 19.2.7. Trulicity (Dulaglutide) Sales Forecast
    • 19.2.8. Victoza (Liraglutide) Sales Forecast
    • 19.2.9. Wegovy (Semaglutide Subcutaneous) Sales Forecast
    • 19.2.10. XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast
    • 19.2.11. Zepbound (Tirzepatide) Sales Forecast
  • 19.3. Phase III GLP-1 Drugs: Sales Forecast
    • 19.3.1. GMA102 / Glutazumab Sales Forecast
    • 19.3.2. JY09 Sales Forecast
    • 19.3.3. LY3298176 / Tirzepatide Sales Forecast
    • 19.3.4. Mazdutide / LY3305677/ IBI-362 Sales Forecast
    • 19.3.5. Orforglipron / LY3502970 Sales Forecast
    • 19.3.6. PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast
    • 19.3.7. Retatrutide / LY3437943 Sales Forecast
    • 19.3.8. Semaglutide Oral Sales Forecast
    • 19.3.9. Semaglutide Subcutaneous Sales Forecast
    • 19.3.10. Survodutide / BI 456906 Sales Forecast
    • 19.3.11. XW003 / Ecnoglutide Sales Forecast
    • 19.3.12. YN011-isupaglutide Sales Forecast

20 GLP-1 MARKET, BY LEADING DRUG DEVELOPERS

  • 20.1. Chapter Overview
  • 20.2. GLP-1 Market: Distribution by Leading Drug Developers, 2020 (USD Million)
  • 20.3. GLP-1 Market: Distribution by Leading Drug Developers, 2024 (USD Million)
  • 20.4. GLP-1 Market: Distribution by Leading Drug Developers, 2035 (USD Million)

21 APPENDIX 1: TABULATED DATA

22 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 6.1. List of GLP-1 Drugs
  • Table 6.2. List of GLP-1 Drug Developers
  • Table 7.1. AstraZeneca: Pipeline Portfolio
  • Table 7.2. AstraZeneca: Recent Developments and Future Outlook
  • Table 7.3. D&D Pharmatech: Pipeline Portfolio
  • Table 7.4. D&D Pharmatech: Recent Developments and Future Outlook
  • Table 7.5. Eli Lilly: Pipeline Portfolio
  • Table 7.6. Eli Lilly: Recent Developments and Future Outlook
  • Table 7.7. Novo Nordisk: Pipeline Portfolio
  • Table 7.8. Novo Nordisk: Recent Developments and Future Outlook
  • Table 7.9. Pfizer: Pipeline Portfolio
  • Table 7.10. Pfizer: Recent Developments and Future Outlook
  • Table 7.11. Sanofi: Pipeline Portfolio
  • Table 7.12. Sanofi: Recent Developments and Future Outlook
  • Table 7.13. Tonghua Dongbao Pharmaceutical: Pipeline Portfolio
  • Table 7.14. Tonghua Dongbao Pharmaceutical: Recent Developments and Future Outlook
  • Table 7.15. Vivani: Pipeline Portfolio
  • Table 7.16. Vivani: Recent Developments and Future Outlook
  • Table 8.1. Biolingus: Pipeline Portfolio
  • Table 8.2. Boehringer Ingelheim: Pipeline Portfolio
  • Table 8.3. Gmax Biopharm: Pipeline Portfolio
  • Table 8.4. Hanmi Pharmaceutical: Pipeline Portfolio
  • Table 8.5. PegBio: Pipeline Portfolio
  • Table 8.6. QL Biopharma: Pipeline Portfolio
  • Table 8.7. Roche: Pipeline Portfolio
  • Table 8.8. Sciwind Biosciences: Pipeline Portfolio
  • Table 8.9. Viking Therapeutics: Pipeline Portfolio
  • Table 8.10. vTv Therapeutics: Pipeline Portfolio
  • Table 9.1. GLP-1 Drug Market: List of Partnerships and Collaborations, Since 2020
  • Table 11.1. List of GLP-1 Drugs Forecasted
  • Table 21.1. GLP-1 Drugs: Distribution by Status of Development
  • Table 21.2. GLP-1 Drugs: Distribution by Type of Molecule
  • Table 21.3. GLP-1 Drugs: Distribution by Active Compound Used
  • Table 21.4. GLP-1 Drugs: Distribution by Type of Agonist
  • Table 21.5. GLP-1 Drugs: Distribution by Route of Administration
  • Table 21.6. GLP-1 Drugs: Distribution by Dosing Frequency
  • Table 21.7. GLP-1 Drugs: Distribution by Type of Therapy
  • Table 21.8. GLP-1 Drugs: Distribution by Target Indication
  • Table 21.9. GLP-1 Drugs: Therapeutic Area
  • Table 21.10. GLP-1 Drugs Developer: Distribution by Year of Establishment
  • Table 21.11. GLP-1 Drugs Developer: Distribution by Company Size
  • Table 21.12. GLP-1 Drugs Developer: Distribution by Location of Headquarters
  • Table 21.13. GLP-1 Drugs Developer: Distribution by Location of Headquarters (Country) and Status of Development
  • Table 21.14. Most Active Developers: Distribution by Number of Drugs
  • Table 21.15. AstraZeneca: Annual Revenues, FY 2021-FY 2023 (USD Billion)
  • Table 21.16. D&D Pharmatech: Annual Revenues, FY 2021-FY 2023 (KRW Billion)
  • Table 21.17. Eli Lilly: Annual Revenues, FY 2021-FY 2023 (USD Billion)
  • Table 21.18. Novo Nordisk: Annual Revenues, FY 2021-FY 2023 (DKK Billion)
  • Table 21.19. Pfizer: Annual Revenues, FY 2021-FY 2023 (USD Billion)
  • Table 21.20. Sanofi: Annual Revenues, FY 2021-FY 2023 (EUR Billion)
  • Table 21.21. Tonghua Dongbao Pharmaceutical: Annual Revenues, FY 2021-FY 2023 (RMB Billion)
  • Table 21.22. Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 21.23. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 21.24. Partnerships and Collaborations: Distribution by Focus Area
  • Table 21.25. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
  • Table 21.26. Most Active Players: Distribution by Number of Partnerships
  • Table 21.27. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Deals
  • Table 21.28. Partnerships and Collaborations: Distribution by Local and International Deals
  • Table 21.29. Global GLP-1 Market, Historical Trends (2020-2023) (USD Billion)
  • Table 21.30. Global GLP-1 Market, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario, (USD Billion)
  • Table 21.31. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
  • Table 21.32. GLP-1 Market for Biologics, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.33. GLP-1 Market for Small Molecule, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.34. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
  • Table 21.35. GLP-1 Market for Dulaglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.36. GLP-1 Market for Liraglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.37. GLP-1 Market for Orforglipron, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.38. GLP-1 Market for Retatrutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.39. GLP-1 Market for Semaglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.40. GLP-1 Market for Survodutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.41. GLP-1 Market for Tirzepatide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.42. GLP-1 Market for Other Active Compounds, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.43. GLP-1 Market: Distribution by Type of GLP-1 Agonist Drug, 2020, 2024 and 2035
  • Table 21.44. GLP-1 Market for Long-acting GLP-1 Agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.45. GLP-1 Market for Short-acting GLP-1 Agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.46. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
  • Table 21.47. GLP-1 Market for Single-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.48. GLP-1 Market for Dual-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.49. GLP-1 Market for Tri-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.50. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
  • Table 21.51. GLP-1 Market for Oral Route, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.52. GLP-1 Market for Parenteral Route, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.53. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
  • Table 21.54. GLP-1 Market for Alzheimer's Disease, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.55. GLP-1 Market for Non-alcoholic Steatohepatitis, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.56. GLP-1 Market for Obesity, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.57. GLP-1 Market for Sleep Apnea, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.58. GLP-1 Market for Type 2 Diabetes, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.59. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
  • Table 21.60. GLP-1 Market in North America, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.61. GLP-1 Market in US, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.62. GLP-1 Market in Canada, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.63. GLP-1 Market in Europe, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.64. GLP-1 Market in Germany, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.65. GLP-1 Market in UK, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.66. GLP-1 Market in France, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.67. GLP-1 Market in Italy, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.68. GLP-1 Market in Spain, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.69. GLP-1 Market in Asia Pacific, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.70. GLP-1 Market in China, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.71. GLP-1 Market in Japan, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.72. GLP-1 Market in Australia, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.73. GLP-1 Market in South Korea, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.74. GLP-1 Market in Latin America, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.75. GLP-1 Market in Brazil, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.76. GLP-1 Market in Argentina, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.77. Approved GLP-1 Drug, Feisumei (Benaglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.78. Approved GLP-1 Drug, Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.79. Approved GLP-1 Drug, Mounjaro (Tirzepatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.80. Approved GLP-1 Drug, Ozempic (Semaglutide Subcutaneous) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.81. Approved GLP-1 Drug, Rybelsus (Semaglutide Oral) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.82. Approved GLP-1 Drug, Saxenda (Liraglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.83. Approved GLP-1 Drug, Trulicity (Dulaglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.84. Approved GLP-1 Drug, Victoza (Liraglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.85. Approved GLP-1 Drug, Wegovy (Semaglutide Subcutaneous) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.86. Approved GLP-1 Drug, XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.87. Approved GLP-1 Drug, Zepbound (Tirzepatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.88. Phase III GLP-1 Drug, GMA102 / Glutazumab Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.89. Phase III GLP-1 Drug, JY09 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.90. Phase III GLP-1 Drug, LY3298176 / Tirzepatide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.91. Phase III GLP-1 Drug, Mazdutide / LY3305677/ IBI-362 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.92. Phase III GLP-1 Drug, Orforglipron / LY3502970 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.93. Phase III GLP-1 Drug, PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.94. Phase III GLP-1 Drug, Retatrutide / LY3437943 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.95. Phase III GLP-1 Drug, Semaglutide Oral Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.96. Phase III GLP-1 Drug, Semaglutide Subcutaneous Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.97. Phase III GLP-1 Drug, Survodutide / BI 456906 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.98. Phase III GLP-1 Drug, XW003 / Ecnoglutide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.99. Phase III GLP-1 Drug, YN011-isupaglutide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 21.100. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2020, Conservative, Base and Optimistic Scenario (USD Billion))
  • Table 21.101. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2024, Conservative, Base and Optimistic Scenario (USD Billion))
  • Table 21.102. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales estimated in 2035, Conservative, Base and Optimistic Scenario (USD Billion))

List of Figures

  • Figure 2.1. Research Methodology: Project Methodology
  • Figure 2.2. Research Methodology: Forecast Methodology
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1. Executive Summary: Market Landscape
  • Figure 4.2. Executive Summary: Partnerships and Collaborations
  • Figure 4.3. Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 5.1. Advantage of GLP-1 Drugs
  • Figure 5.2. Challenges Associated with GLP-1 Drugs
  • Figure 5.3. Mechanisms of Action of GLP-1 Drugs
  • Figure 6.1. GLP-1 Drugs: Distribution by Status of Development
  • Figure 6.2. GLP-1 Drugs: Distribution by Type of Molecule
  • Figure 6.3. GLP-1 Drugs: Distribution by Active Compound Used
  • Figure 6.4. GLP-1 Drugs: Distribution by Type of Agonist
  • Figure 6.5. GLP-1 Drugs: Distribution by Route of Administration
  • Figure 6.6. GLP-1 Drugs: Distribution by Dosing Frequency
  • Figure 6.7. GLP-1 Drugs: Distribution by Type of Therapy
  • Figure 6.8. GLP-1 Drugs: Distribution by Target Indication
  • Figure 6.9. GLP-1 Drugs: Distribution by Therapeutic Area
  • Figure 6.10. GLP-1 Drugs Developer: Distribution by Year of Establishment
  • Figure 6.11. GLP-1 Drugs Developer: Distribution by Company Size
  • Figure 6.12. GLP-1 Drugs Developer: Distribution by Location of Headquarters
  • Figure 6.13. GLP-1 Drugs Developer: Distribution by Location of Headquarters (Country) and Status of Development
  • Figure 6.14. Most Active Developers: Distribution by Number of Drugs
  • Figure 7.1. AstraZeneca: Annual Revenues, FY 2021-FY 2023 (USD Billion)
  • Figure 7.2. D&D Pharmatech: Annual Revenues, FY 2021-FY 2023 (Korean Won Billion)
  • Figure 7.3. Eli Lilly: Annual Revenues, FY 2021-FY 2023 (USD Billion)
  • Figure 7.4. Novo Nordisk: Annual Revenues, FY 2021-FY 2023 (DKK Billion)
  • Figure 7.5. Pfizer: Annual Revenues, FY 2021-FY 2023 (USD Billion)
  • Figure 7.6. Sanofi: Annual Revenues, FY 2021-FY 2023 (EUR Billion)
  • Figure 7.7. Tonghua Dongbao Pharmaceutical: Annual Revenues, FY 2021-FY 2023 (RMB Billion)
  • Figure 9.1. Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3. Partnerships and Collaborations: Distribution by Focus Area
  • Figure 9.4. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
  • Figure 9.5. Most Active Players: Distribution by Number of Partnerships
  • Figure 9.6. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Deals
  • Figure 9.7. Partnerships and Collaborations: Distribution by Local and International Deals
  • Figure 10.1. GLP-1 Drugs: Market Drivers
  • Figure 10.2. GLP-1 Drugs: Market Restraints
  • Figure 10.3. GLP-1 Drugs: Market Opportunities
  • Figure 10.4. GLP-1 Drugs: Market Challenges
  • Figure 11.1. Global GLP-1 Market, Historical Trends and Forecasted Estimates, till 2035
  • Figure 11.2. Global GLP-1 Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Billion)
  • Figure 11.3. Global GLP-1 Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Billion)
  • Figure 12.1. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
  • Figure 12.2. GLP-1 Market for Biologics, till 2035 (USD Billion)
  • Figure 12.3. GLP-1 Market for Small Molecule, till 2035 (USD Billion)
  • Figure 13.1. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
  • Figure 13.2. GLP-1 Market for Dulaglutide, till 2035 (USD Billion)
  • Figure 13.3. GLP-1 Market for Liraglutide, till 2035 (USD Billion)
  • Figure 13.4. GLP-1 Market for Orforglipron, till 2035 (USD Billion)
  • Figure 13.5. GLP-1 Market for Retatrutide, till 2035 (USD Billion)
  • Figure 13.6. GLP-1 Market for Semaglutide, till 2035 (USD Billion)
  • Figure 13.7. GLP-1 Market for Survodutide, till 2035 (USD Billion)
  • Figure 13.8. GLP-1 Market for Tirzepatide, till 2035 (USD Billion)
  • Figure 13.9. GLP-1 Market for Other Active Compounds, till 2035 (USD Billion)
  • Figure 14.1. GLP-1 Market: Distribution by Type of GLP-1 Agonist Drug, 2020, 2024 and 2035
  • Figure 14.2. GLP-1 Market for Long-acting GLP-1 Agonist, till 2035 (USD Billion)
  • Figure 14.3. GLP-1 Market for Short-acting GLP-1 Agonist, till 2035 (USD Billion)
  • Figure 15.1. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
  • Figure 15.2. GLP-1 Market for Single-agonist, till 2035 (USD Billion)
  • Figure 15.3. GLP-1 Market for Dual-agonist, till 2035 (USD Billion)
  • Figure 15.4. GLP-1 Market for Tri-agonist, till 2035 (USD Billion)
  • Figure 16.1. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
  • Figure 16.2. GLP-1 Market for Oral, till 2035 (USD Billion)
  • Figure 16.3. GLP-1 Market for Parenteral, till 2035 (USD Billion)
  • Figure 17.1. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
  • Figure 17.2. GLP-1 Market for Alzheimer's Disease, till 2035 (USD Billion)
  • Figure 17.3. GLP-1 Market for Non-alcoholic Steatohepatitis, till 2035 (USD Billion)
  • Figure 17.4. GLP-1 Market for Obesity, till 2035 (USD Billion)
  • Figure 17.5. GLP-1 Market for Sleep Apnea, till 2035 (USD Billion)
  • Figure 17.6. GLP-1 Market for Type 2 Diabetes, till 2035 (USD Billion)
  • Figure 18.1. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
  • Figure 18.2. GLP-1 Market in North America, till 2035 (USD Billion)
  • Figure 18.3. GLP-1 Market in Europe, till 2035 (USD Billion)
  • Figure 18.4. GLP-1 Market in Asia Pacific, till 2035 (USD Billion)
  • Figure 18.5. GLP-1 Market in Latin America, till 2035 (USD Billion)
  • Figure 19.1. Approved GLP-1 Drug, Feisumei (Benaglutide) Sales Forecast, till 2035 (USD Billion)
  • Figure 19.2. Approved GLP-1 Drug, Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast, till 2035 (USD Billion)
  • Figure 19.3. Approved GLP-1 Drug, Mounjaro (Tirzepatide) Sales Forecast, till 2035 (USD Billion)
  • Figure 19.4. Approved GLP-1 Drug, Ozempic (Semaglutide Subcutaneous) Sales Forecast, till 2035 (US D Billion)
  • Figure 19.5. Approved GLP-1 Drug, Rybelsus (Semaglutide Oral) Sales Forecast, till 2035 (USD Billion)
  • Figure 19.6. Approved GLP-1 Drug, Saxenda (Liraglutide) Sales Forecast, till 2035 (USD Billion)
  • Figure 19.7. Approved GLP-1 Drug, Trulicity (Dulaglutide) Sales Forecast, till 2035 (USD Billion)
  • Figure 19.8. Approved GLP-1 Drug, Victoza (Liraglutide) Sales Forecast, till 2035 (USD Billion)
  • Figure 19.9. Approved GLP-1 Drug, Wegovy (Semaglutide Subcutaneous) Sales Forecast, till 2035 (USD Billion)
  • Figure 19.10. Approved GLP-1 Drug, XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast, till 2035 (USD Billion)
  • Figure 19.11. Approved GLP-1 Drug, Zepbound (Tirzepatide) Sales Forecast, till 2035 (USD Billion)
  • Figure 19.12. Phase III GLP-1 Drug, GMA102 / Glutazumab Sales Forecast, till 2035 (USD Billion)
  • Figure 19.13. Phase III GLP-1 Drug, JY09 Sales Forecast, till 2035 (USD Billion)
  • Figure 19.14. Phase III GLP-1 Drug, LY3298176 / Tirzepatide Sales Forecast, till 2035 (USD Billion)
  • Figure 19.15. Phase III GLP-1 Drug, Mazdutide / LY3305677/ IBI-362 Sales Forecast, till 2035 (USD Billion)
  • Figure 19.16. Phase III GLP-1 Drug, Orforglipron / LY3502970 Sales Forecast, till 2035 (USD Billion)
  • Figure 19.17. Phase III GLP-1 Drug, PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast, till 2035 (USD Billion)
  • Figure 19.18. Phase III GLP-1 Drug, Retatrutide / LY3437943 Sales Forecast, till 2035 (USD Billion)
  • Figure 19.19. Phase III GLP-1 Drug, Semaglutide Oral Sales Forecast, till 2035 (USD Billion)
  • Figure 19.20. Phase III GLP-1 Drug, Semaglutide Subcutaneous Sales Forecast, till 2035 (USD Billion)
  • Figure 19.21. Phase III GLP-1 Drug, Survodutide / BI 456906 Sales Forecast, till 2035 (USD Billion)
  • Figure 19.22. Phase III GLP-1 Drug, XW003 / Ecnoglutide Sales Forecast, till 2035 (USD Billion)
  • Figure 19.23. Phase III GLP-1 Drug, YN011-isupaglutide Sales Forecast, till 2035 (USD Billion)
  • Figure 20.1. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2020 (USD Billion))
  • Figure 20.2. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2024 (USD Billion))
  • Figure 20.3. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales estimated in 2035 (USD Billion))